CN119156400A - 包含结合存在于靶细胞的细胞表面上的人srrm2的抗体的组合物 - Google Patents

包含结合存在于靶细胞的细胞表面上的人srrm2的抗体的组合物 Download PDF

Info

Publication number
CN119156400A
CN119156400A CN202380025366.1A CN202380025366A CN119156400A CN 119156400 A CN119156400 A CN 119156400A CN 202380025366 A CN202380025366 A CN 202380025366A CN 119156400 A CN119156400 A CN 119156400A
Authority
CN
China
Prior art keywords
amino acid
acid sequence
seq
antibody
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380025366.1A
Other languages
English (en)
Chinese (zh)
Inventor
R·蔡德勒
K·格特纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aximian Biotechnology Co ltd
Munich University Medical Center
Helmholtz Munich Center German Center For Health And Environmental Research Ltd
Original Assignee
Aximian Biotechnology Co ltd
Munich University Medical Center
Helmholtz Munich Center German Center For Health And Environmental Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aximian Biotechnology Co ltd, Munich University Medical Center, Helmholtz Munich Center German Center For Health And Environmental Research Ltd filed Critical Aximian Biotechnology Co ltd
Publication of CN119156400A publication Critical patent/CN119156400A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN202380025366.1A 2022-03-14 2023-03-14 包含结合存在于靶细胞的细胞表面上的人srrm2的抗体的组合物 Pending CN119156400A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22161839.0 2022-03-14
EP22161839 2022-03-14
PCT/EP2023/056397 WO2023174897A1 (en) 2022-03-14 2023-03-14 Composition comprising an antibody which binds to human srrm2 present on the cell surface of a target cell

Publications (1)

Publication Number Publication Date
CN119156400A true CN119156400A (zh) 2024-12-17

Family

ID=80738871

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380025366.1A Pending CN119156400A (zh) 2022-03-14 2023-03-14 包含结合存在于靶细胞的细胞表面上的人srrm2的抗体的组合物

Country Status (6)

Country Link
EP (1) EP4493587A1 (https=)
JP (1) JP2025510642A (https=)
KR (1) KR20250099050A (https=)
CN (1) CN119156400A (https=)
CA (1) CA3245743A1 (https=)
WO (1) WO2023174897A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025255706A1 (en) * 2024-06-11 2025-12-18 Zeno Therapeutics Pte. Ltd. Diagnosis and treatment of aml
WO2025054760A1 (en) * 2023-09-11 2025-03-20 Zeno Therapeutics (Shenzhen) Co. Ltd. Composition comprising an antibody which binds to human srrm2 present on the cell surface of a target cell
WO2025056603A1 (en) * 2023-09-11 2025-03-20 Eximmium Biotechnologies Gmbh Srrm2 binders for treating and diagnosing blood cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2595638T3 (es) * 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR

Also Published As

Publication number Publication date
CA3245743A1 (en) 2023-09-21
WO2023174897A1 (en) 2023-09-21
EP4493587A1 (en) 2025-01-22
JP2025510642A (ja) 2025-04-15
KR20250099050A (ko) 2025-07-01

Similar Documents

Publication Publication Date Title
EP4640710A1 (en) Monoclonal antibody specifically binding to claudin-18.2 and use thereof
AU2007318483B2 (en) Anti-human Dlk-1 antibody showing anti-tumor activity in vivo
CN119156400A (zh) 包含结合存在于靶细胞的细胞表面上的人srrm2的抗体的组合物
EP2275537B1 (en) Anti-human dlk-1 antibody having anti-tumor activity in vivo
JP7024072B2 (ja) 抗ｃｄ３抗体およびそれを含む癌処置用医薬組成物
CN103534272A (zh) 能够特异性识别转铁蛋白受体的抗体
CN109988240B (zh) 抗gpc-3抗体及其用途
CN111247173A (zh) 抗msln抗体及包含其的用于癌症治疗的药物组合物
US9273140B2 (en) Antibody for detecting DNA damage in cells utilizing cell membrane surface antigen Ly6D
US7396915B2 (en) Monoclonal antibody and gene encoding the same, hybridoma, pharmaceutical composition, and diagnostic reagent
JP2019512548A (ja) ポドカリキシン及びｔｒａ関連抗体、調製方法、並びに抗癌治療剤としての使用
US20240050475A1 (en) Composition comprising an antibody which binds to human prdx4 present on the cell surface of a target cell
CN116981688A (zh) 包含结合存在于靶细胞的细胞表面上的人prdx4的抗体的组合物
WO2025125557A1 (en) Composition comprising an antibody which binds to human igf2bp1 present on the cell surface of a target cell
WO2025054760A1 (en) Composition comprising an antibody which binds to human srrm2 present on the cell surface of a target cell
WO2025255706A1 (en) Diagnosis and treatment of aml
CN100543135C (zh) 单克隆抗体及编码其的基因、药物组合物和诊断试剂
RU2774710C2 (ru) Антитело против подокаликсина и tra-родственного белка, способы его получения и применения в качестве противоопухолевого терапевтического средства
AU2024340551A1 (en) Srrm2 binders for treating and diagnosing blood cancer
JP2005040126A (ja) モノクローナル抗体およびそれをコードする遺伝子、ハイブリドーマ、医薬組成物ならびに診断試薬
HK40107987A (zh) 抗紧密连接蛋白-6的抗体及其用途
CN117597362A (zh) 抗紧密连接蛋白-6的抗体及其用途
CN119985271A (zh) 表面srrm2作为aml的预后生物标志物和免疫疗法的分子靶标
HK40021332B (zh) 抗-cd3抗体及包含其的用於癌症治疗的药物组合物
HK40021332A (en) Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination